Low prevalence of VRE gastrointestinal colonization of hospitalized patients in Manitoba tertiary care and community hospitals

Canadian Journal of Infectious Diseases

Volumn 11, Issue 1, 2000, Pages 38-41

  Zhanel, George G ^a,b,c   Harding, Godfrey K M ^a,b,c,d   Rosser, Stuart ^a,c   Hoban, Daryl J ^a,c   Karlowsky, James A ^a,b,c   Alfa, Michelle ^a,d   Kabani, Amin ^a,c   Embil, John ^a,c   Gin, Alfred ^b,c   Williams, Trevor ^a,c   Nicolle, Lindsay E ^a,c  

^a UNIVERSITY OF MANITOBA   (Canada)

^b UNIVERSITY OF MANITOBA   (Canada)

^c HEALTH SCIENCES CENTRE   (Canada)

^d ST BONIFACE GENERAL HOSPITAL   (Canada)

Author keywords

Manitoba; Prevalence; Vancomycin resistant enterococci

Indexed keywords

AMPICILLIN; ANTIINFECTIVE AGENT; COLISTIN; DALFOPRISTIN PLUS QUINUPRISTIN; GENTAMICIN; NALIDIXIC ACID; ORITAVANCIN; STREPTOMYCIN; TEICOPLANIN; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM ISOLATE; CANADA; CLOSTRIDIUM DIFFICILE; COMMUNITY HOSPITAL; ENTEROCOCCUS; ENTEROCOCCUS FAECIUM; ENTEROCOCCUS GALLINARUM; FECES ANALYSIS; HUMAN; NONHUMAN;

EID: 0034092028     PISSN: 11802332     EISSN: None     Source Type: Journal    
DOI: 10.1155/2000/356317     Document Type: Article

References (21)

1. Currie BP, Gnass S, Levi MH. A hospital based stool culture survey to detect vancomycin resistant enterococcus (VRE)-Utility and application. Infect Control Hosp Epidemiol 1995;16(Suppl):P18. (Abst 15)
2. Gin AS, Zhanel GG. Vancomycin resistant enterococci (VRE). Am Pharmacother 1996;30:615-24.
3. Bacquero F. Gram-positive resistance: challenge for the development of new antibiotics. J Antimicrob Chemother 1997;39(Suppl A):1-6.
4. Embil J, Zhanel G, Kabani A, Nicolle L. Low prevalence of gastrointestinal colonization with antimicrobial resistant bacteria in high risk units in a Canadian tertiary care centre. Can Infect Dis 1996;7:307-12.
5. Edmond MB, Ober JF, Weinbaum DL, et al. Vancomycin-resistant Enterococcus faecium bacteremia: risk factors for infection. Clin Infect Dis 1995;20:1126-33.
6. Recommendations for preventing the spread of vancomycin resistance. MMWM Morb Mortal Wkly Rep 1995;44(RR1-12):1-19.
7. Devriese LA, Pot B, Kersters K, Lauwers S, Haesebrouck F. Acidification of methyl-a-D-glucopyranoside: a useful test to differentiate Enterococcus casseliflavus and Enterococcus gallinarum from Enterococcus faecium species group and from Enterococcus faecalis. J Clin Microbial 1996;34:2607-8.
8. Turenne CY, Hoban DJ, Karlowsky JA, Zhanel GG, Kabani AM. Screening of stool samples for identification of vancomycin-resistant enterococcus isolates should include the methyl-alpha-D-glucopyranoside test to differentiate nonmotile Enterococcus gallinarum from E. faecium. J Clin Microbiol 1998;36:2333-5.
9. Landman D, Quale JM, Oydna E, et al. Comparison of five selective media for identifying fecal carriage of vancomycin-resistant enterococci. J Clin Microbiol 1996;34:751-2.
10. Williams AM, Rodrigues UM, Collins MD. Intragenenic relationships of enterococci as determined by reverse transcriptase sequencing of small-subunit rRNA. Res Microbial 1991;142:67-74.
11. Dutka-Malen S, Evers S, Courvalin P. Detection of glycopeptide resistance genotypes and identification to the species level of clinically relevant enterococci by PCR. J Clin Microbiol 1995;33:24-7.
12. Clark NC, Cooksey RC, Hill BC, Swenson JM, Tenover FC. Characterization of glycopeptide resistant enterococci from US hospitals. Antimicrob Agents Chemother 1993;37:2311-7.
13. National Committee of Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Testing for bacteria That Grow Aerobically: Approved Standard M7-A4. Wayne: NCCLS, 1997.
14. National Committee of Clinical Laboratory Standards. Performance Standards for Antimicrobial Susceptibility Testing; Eighth Informational Supplement M100-S8. Wayne: NCCLS, 1998.
15. French GL. Enterococci and vancomycin resistance. Clin Infect Dis 1998;27(Suppl 1):S75-83.
16. Toala P, McDonald A, Wilcox C, Finland M. Susceptibility of group D Streptococcus (Enterococcus) to 21 antibiotics in vitro with special reference to species differences. Am J Med Sci 1969;258:416-30.
17. Harwick HJ, Kalmanson GM, Guze LB. In vitro activity of ampicillin or vancomycin combined with gentamicin or streptomycin against enterococci. Antimicrob Agents Chemother 1973;4:383-7.
18. Uttley AHC, Collins CH, Naidoo, J George RC. Vancomycin-resistant enterococci. Lancet 1988;i:57-8.
19. Nosocomial enterococci resistant to vancomycin - United States, 1989-1993. MMWR Morb Mortal Wkly Rep 1993;42:597-9.
20. Emerging epidemiology of vancomycin-resistant enterococci in Canada. Can J Infect Dis 1997;8:182-5.
21. Ofner-Agostini ME, Conly J, Paton S, et al. Vancomycin-resistant enterococci (VRE) in Canada - Results of the Canadian nosocomial infection surveillance program 1996 VRE point prevalence surveillance project. Can J Infect Dis 1997;8:73-8.